

INDUSTRIAL PROPERTY AGENTS

Malderen, Lic. Chim. Lg (1,2,3,5)
 rers, Phys. Dipl. EPZF (1,3,5)
 Malderen, Ir. Civ. Phys. (1,2,3,5)
 Malderen, Lic. Sc. Biol. (2,3,5)
 plôme C.E.I.P.I. Brevets) (5)
 nslaus, Lic. Droit (1,2)
 dersteen, Bio Ir. (5)
 smet

ho, Dr. Chim. Phys.
 naret-Prodhomme, Dr. Sc.
 yssel, Burg. Ir. Electromec.
 k, Lic. Sc. Chim.
 len, Lic. Rechten
 n Bladel, Burg. Ir. Electr.
 roofs, Dr. Bio Ir.

IF COUNSEL

ops, Lic. Rechten (1,2)
 shels, Lic. Phys. Chim. (1,4)
 kowska, Ir. Electr.

ropean Patent Attorney
 lgian Patent Attorney
 xembourg Patent Attorney
 nch Patent Attorney
 ropean Trademark Attorney



Office Van Malderen

Member of Pro Novem Group

BE04/00134

B-1083 Brussels (Belgium)

Place Reine Fabiola 6/1

Telephone + 32 2 4263810

Telefax + 32 2 4263760

E-mail vanmalderen@pronovem.com

Web site www.pronovem.com

V.A.T.: BE 473.077.314

T.R. Brussels: 644.874

° SERVICE PUBLIC FEDERAL ECONOMIE
 OFFICE DE LA PROPRIETE INTELLECT.

North Gate III, 5e étage
 Bld du Roi Albert II, 16
 B-1000 BRUXELLES

REC'D 15 DEC 2004

WIPO

PCT

Brussels, 18/11/2004

Re.: PATENT - Extension - W.I.P.O.

Application No. PCT/BE2004/00134, filed on 22/09/2004
 in the name of FNDP + ULB

Y. Ref.

O. Ref. P.FNDP.017B/WO

Dear Sirs:

This is further to the invitation to correct defects in the
 International application.

In order to meet the PCT requirements for the above mentioned patent
 application, please find herewith enclosed :

- Priority document EP 03447231.6 filed 22/09/2003


Very truly yours,

OFFICE VAN MALDEREN


 Joëlle VAN MALDEREN (1003)

Encl.: as stated

PRIORITY DOCUMENT
 SUBMITTED OR TRANSMITTED IN
 COMPLIANCE WITH
 RULE 17.1(a) OR (b)



G:\CHRONO\2004 11\P FNDP 017 WO 3.doc
 G:\DOSSIER\PFNDP\017\WO\2004 11 3.doc

Office Van Malderen S.A./N.V.

Place Reine Fabiola 6/1

B-1083 Bruxelles

Tel.: +32 2 4263810 Fax: +32 2 4263760

Pro Novem Group

Bruges
 Liège
 France
 Luxembourg

Spoorwegstraat 20
 Bd de la Sauvenière 85/043
 10 Avenue de la Créativité
 B.P. 111 Route d'Arlon 261

B-8200 Brugge
 B-4000 Liège
 F-59650 Villeneuve d'Ascq
 L-8002 Strassen

Tel.: +32 50 406370 Fax: +32 50 396408
 Tel.: +32 4 2305400 Fax: +32 4 2229061
 Tel.: +33 3 20561944 Fax: +33 3 20348241
 Tel.: +352 313770 Fax: +352 313773

Banks: Post Giro BE63 0000 9180 1608

Fortis

BE16 2100 5964 7574

Dexia

BE32 5522 9311 0002

RECEIVED COPY



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

REC'D 15 DEC 2004

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°


03447231.6

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk





Anmeldung Nr.:
Application no.: 03447231.6
Demande no:

Anmeldetag:
Date of filing: 22.09.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Facultés Universitaires Notre-Dame de la
Paix
Rue de Bruxelles, 61
5000 Namur
BELGIQUE
UNIVERSITE LIBRE DE BRUXELLES
50, avenue F.D. Roosevelt,
CP 165
B-1050 Bruxelles
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

2-pyridinone derivatives, having hiv inhibiting properties

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07D211/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

2-PYRIDINONE DERIVATIVES, HAVING HIV INHIBITING PROPERTIES

10 Field of the invention

[0001] The present invention relates to 2-pyridinone derivatives, in particular 5-ethyl-6-methyl-2-pyridinone derivatives, that inhibit HIV, especially human immunodeficiency virus type 1 (HIV-1) replication and are
15 therefore of interest in the treatment of Acquired Immune Deficiency Syndrome (AIDS). The present invention further relates to the synthesis of said compounds and their use, whether or not in combination with other pharmaceutical and/or therapeutic agents, in the treatment of viral
20 infectious diseases like AIDS, especially viral infections by HIV-1.

Background of the invention

[0002] Human Immunodeficiency Virus (HIV) is the
25 causative agent of AIDS. Two main forms of this virus (HIV-1 and HIV-2) have been identified. HIV-0 is a subtype of HIV-1. HIV-1, HIV-2 and HIV-0 are all causative agents of AIDS, of which HIV-1 is the most common one. As a retrovirus from the lentivirus family, HIV has its genome
30 in the form of single-stranded RNA.

[0003] An essential step of HIV lifecycle is therefore the reverse transcription of this single stranded RNA into double-stranded DNA. This process is catalyzed by a virally encoded enzyme known as reverse transcriptase. Numerous

reverse transcriptase inhibitors have been used as antiretroviral agents. Most of them can be classified either as nucleoside reverse transcriptase inhibitors (NRTIs), also known as nucleoside analogues, or as non-nucleoside reverse transcriptase inhibitors (NNRTIs) that bind at an allosteric site (referred to as "TIBO site") some 10 Å from the catalytic site. Most NNRTIs display marked selectivity for HIV-1 inhibition.

10 State of the art

[0004] European patent application EP0462800 describes a first series of pyridinone derivatives and their use in the treatment of HIV-related diseases.

15 [0005] European patent application EP0462808 discloses a series of pyridinone derivatives that are structurally related to those of EP0462800 and also find their use in the treatment of HIV-related diseases.

[0006] European patent application EP0481802 describes the preparation of 2-pyridinones and 2-pyridinethiones and
20 their use in the treatment of HIV-related diseases.

[0007] International patent application WO97/05113 discloses the preparation of 4-aryl-thio-pyridinones and their use in the treatment of HIV-related diseases.

[0008] International patent application WO02/08226
25 ~~discloses tricyclic 2-pyridinone compounds which are useful~~
as inhibitors of HIV reverse transcriptase.

[0009] Published US patent application US2003125340 discloses 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.

30 [0010] International patent application WO99/55676 discloses the preparation of 3-amino- and 3-aminoalkyl-pyridinone and pyridinethione derivatives and their use in the treatment of HIV-related diseases.

[0011] International patent application WO02/24650 and European patent application EP 1 318 995 disclose another series of pyridinone and pyridinethione derivatives displaying HIV inhibiting properties.

5 [0012] The present invention provides still further antiviral agents with excellent activity against HIV-1 infections.

Aims of the invention

10 [0013] The present invention aims to provide new antiviral agents that are able to prevent, inhibit and/or suppress viral infections and that show especially improved inhibitory action towards Human Immunodeficiency Virus type 1 (HIV-1) replication (reversible or irreversible
15 inhibitors active against wild-type and mutant strains).


[0014] In particular, the present invention aims to provide such compounds which are non-nucleoside reverse transcriptase inhibitors (NNRTIs), able to block HIV-1 replication, and which do not require metabolic activation
20 (e.g. phosphorylation) to be active.

[0015] A further aim of the present invention is to provide such compounds, which can be used in the prevention, suppression and/or the treatment of viral infections, either as pure compounds, as pharmaceutically
25 acceptable salts or as prodrug thereof and/or as ingredient of a pharmaceutical composition, possibly in combination with other antiviral active agents and/or immunomodulators.


[0016] A last aim of the present invention is to provide methods of synthesis for such compounds and to
30 provide compounds obtainable by said methods.

Summary of the invention

[0017] One aspect of the invention concerns the antiviral compounds of claim 1. In particular, the present




R1 =



Ar = Aromatic ring selected from : phenyl, pyridyl, thiazolyl, furanyl, thiophenyl, benzofuranyl, benzothiophenyl, benzothiazolyl, imidazolyl, indolyl, each optionally substituted with up to 4 substituents selected from : halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido

Y = H, halo, alkylamino, dialkylamino, nitrile, hydroxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy, C₅₋₇ cycloalkyl optionally substituted with up to 4 substituents selected from : halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, nitrile; or Y can be :



R₂ = C₇₋₉ cycloalkyl;

C₅₋₈ cycloalkyl substituted with up to 4 substituents;

C₅₋₈cycloalkenyl optionally substituted with up to 4 substituents;


C₅₋₈aliphatic heterocycle optionally substituted with up to 4 substituents;

C₆₋₉bridged cycloalkyl optionally substituted with up to 4 substituents;


C₆₋₉bridged cycloalkenyl optionally substituted with up to 4 substituents;

substituents selected from :

halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, CN;



Or R2 can be :



[0018] The present invention is also related to pharmaceutically acceptable salts or prodrugs of said compounds as well as to a pharmaceutical composition comprising at least one of the different compounds according to the invention (in pure form and/or as acceptable salt and/or as prodrug) and further an adequate pharmaceutical carrier and/or diluent. The compounds according to the invention may be used in combination with any other suitable (known or yet unknown) antiviral compounds, anti-infective agents, immunomodulators, antibiotics and/or vaccines.

[0019] Said pharmaceutical composition can find advantageous and efficient use in the prevention, treatment and/or the suppression of viral infections by Human Immunodeficiency Virus type 1 (HIV-1).

~~[0020]~~ Another aspect of the present invention is related to the use of any of the compounds according to the invention (in pure form and/or as salt and/or as prodrug) or the pharmaceutical composition according to the invention as a medicament and/or for the manufacture of a medicament to treat, suppress and/or prevent viral infections induced by Human Immunodeficiency Virus type 1 (HIV-1).

[0021] A final aspect of the present invention is related to the preparation method of said compounds as described in detail hereafter.

[0022] The following examples and specific embodiments are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

Brief description of the Figures

10 [0023] The Figure 1 represents the synthesis of ethyl 4-[(3,5-dimethylcyclohexyl)oxy]-5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (compound Z37).

[0024] The Figure 2A and 2B represent respectively the X-ray structure of compound Z37A and Z37inv.

15 [0025] The Figure 3 represents the synthesis of 4-(cycloheptyloxy)-3-(hydroxymethyl)-5-ethyl-6-methylpyridine-2(1H)-one (compound Z32).

[0026] The Figure 4 represents the synthesis of [4-(cycloheptyloxy)-5-ethyl-6-methyl-2-oxo-1,2-dihydropyridine-3-yl]methyl chloroacetate (compound Z33).

20 [0027] The Figure 5 represents the synthesis of 2-(dimethylamino)ethyl 4-[(3,5-dimethylcyclohexyl)oxy]-5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (compound Z53).

25 [0028] The Figure 6 represents the synthesis of ethyl 5-ethyl-6-methyl-4-[(3-methylbut-2-enoyl)oxy]-2-oxo-1,2-dihydropyridine-3-carboxylate (compound M18).

[0029] The Figure 7 represents general formula I.

30 Detailed description of the invention

[0030] Compounds of general formula I (see above) that are described in the present invention behave either as reversible reverse transcriptase inhibitors or as irreversible reverse transcriptase inhibitors. The

following two-step mechanism is thought to be involved in irreversible inhibition:

1. reversible binding to the allosteric site (TIBO site) of HIV-1 reverse transcriptase, and
- 5 2. formation of a covalent bond with a reactive amino-acid of the TIBO site, leading to irreversible inhibition


[0031] Of particular interest are compounds of formula I with a specific substitution in position 4 of the
 10 pyridinone ring. Such compounds show an excellent antiviral activity against HIV-1. A particular example hereof is for instance compound Z37, which bears a 3,5-dimethylcyclohexyl moiety as R2 (see general formula above).

[0032] Some of the compounds according to the present
 15 invention were found to exhibit an excellent antiviral activity against HIV-1 mutant strains that are resistant to one or more antiviral agents active against HIV-1 such as commonly applied NNRTIs like Nevirapine.

20 Examples

Example 1: Synthesis of ethyl 4-[(3,5-dimethylcyclohexyl)oxy]-5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (compound Z37)

[0033] Compound Z37 which corresponds to formula II



(formula II)

25

was synthesized, following a three-step protocol, as described below and as illustrated in Figure 1.

Step 1

[0034] ethyl 4-hydroxy 5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (B0) was synthesized as described by E. Bisagni and al. (J.Med.Chem. 1995, 38, 4679-4686). Then, benzyl bromide (1.8g, 10.5 mmol) was added to a stirred suspension of silver carbonate (1.41g, 5.1mmol) and B0 (2.25g, 10mmol). The mixture was heated (50°C) overnight then cooled and filtered over celite 521 (Aldrich). The solvent was evaporated and the crude product purified using a silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: pentane/dichloromethane, 70/30 v/v%), to give intermediate A (2.6g, 83% yield).

15 Step 2

[0035] In a second step, Diisopropyl azodicarboxylate (DIAD) (0.804g, 4 mmol) was added drop wise at room temperature to a solution of intermediate A (0.63 g, 2 mmol), triphenylphosphine ($P\Phi_3$) (1.048g, 4 mmol) and 3,5-dimethylcyclohexanol (0.512g, 4 mmol) in THF (20ml). After stirring overnight, the THF was evaporated and the residue was suspended in a mixture of hexane and diethyl ether (50:50 v/v%). The precipitate was filtered off and the organic layer was evaporated. The residue obtained was purified using a silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: pentane/dichloromethane, 50/50 v/v%), to give intermediate B (0.595 g, 70% yield).

Step 3

30 [0036] In a third step, Pd/C 10% (w/w%) (0.160g) was added to a solution of intermediate B (0.360g, 0.89 mmol) in cyclohexane (4ml) and diisopropyl ether (12 ml). The mixture was heated overnight at 70°C. The precipitate was then filtered off and the organic solvents were evaporated.

The product was purified with a silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: dichloromethane/ethanol, 95/05 v/v%) to give product Z37 as a mixture of stereoisomers (0.238 g, 80% yield, mp (melting point) for the mixture of stereoisomers = 108°C).

[0037] The major isomer of the mixture, Z37A (70%) was purified by chiral HPLC (e.g. using a DAICEL chiralpak AD 4,6/250mm column; eluent: hexane/isopropanol 95/05 v/v%). (mp= 122°C).

10 [0038] A nuclear magnetic resonance (NMR) ¹H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound Z37A:
NMR ¹H for Z37A: δ 13 (s, 1H), 4.7 (m, 1H), 4.4 (q, 2H), 2.4 (q, 2H), 2.25 (s, 3H), 2.15-1.6 (m, 8H), 1.35 (t, 3H),
15 1.0 (t, 3H), 0.85 (d, 6H)

[0039] A diastereoisomeric form of Z37A (Z37inv) was obtained by a stereoselective double Mitsunobu reaction (mp= 158°C) (David L. Hugues 1992, "The mitsunobu reaction", Organic Reaction, 42, 335). Its antiviral
20 activity was found to be higher than the activity observed for either Z37A or the mixture of stereoisomers (see infra).

[0040] The stereochemistry of compounds Z37A and Z37inv was checked by X-Ray diffraction using a Enraf-
25 Nonius CAD-4 apparatus (Brucker). The X-Ray diffraction structures of both compounds are given in Figures 2 A and B respectively. The crystal data of both compounds, as well as the specific data collection information and applied refinement conditions, are summarized in Table 1.

Table 1: Crystal data, data collection and refinement information for compounds Z37A and Z37inv (symbols used are standard IUPAC symbols well known in the art)


	Z37A	Z37inv
Crystal Data		
Formula	$C_{19}H_{29}NO_4$	$C_{19}H_{29}NO_4$
MW	335.43	335.43
System, space group	Triclinic, P-1	Monoclinic, P21/c
a (Å)	8.518 (1)	13.488 (3)
b (Å)	9.220 (2)	9.064 (2)
c (Å)	13.436 (1)	16.584 (1)
α (°)	88.906 (6)	90.0
β (°)	82.053 (4)	110.617 (16)
γ (°)	66.369 (7)	90.0
V (Å ³)	956.7 (2)	1897.6 (6)
Z	2	4
D _x (Mg m ⁻³)	1.164	1.174
Radiation	Cu K α	Cu K α
μ (mm ⁻¹)	0.651	0.066
T (K)	293 (2)	293 (2)
Crystal	Platelet, colourless	Platelet, colourless
Crystal size	0.34 x 0.30 x 0.13	0.45 x 0.34 x 0.25
Data collection		
Diffractometer	Enraf-Nonius CAD-4	Enraf-Nonius CAD-4
Scan	$\theta/2\theta$	$\theta/2\theta$
Absorption correction	Analytical $T_{\min}=0.809$, $T_{\max}=0.920$	None
Measured reflections	4012	4075
Independent reflections	3764	3907
Reflections with $I > 2 \sigma(I)$	3067	3223
R _{int}	0.0137	0.0967
θ_{\max}	71.97	74.98
h	-9 -> 10	0 -> 16
k	0 -> 11	0 -> 11
l	-16 -> 16	-20 -> 19

Table 1: continuation

Refinement		
Refinement on	F^2	F^2
$R[F^2 > 2 \sigma(F^2)]$	0.0526	0.0825
$wR(F^2)$	0.1759	0.2150
S	1.462	1.689
Number of reflections	3764	3907
Number of parameters	223	221
$(\Delta/\sigma)_{\max}$	0.013	0.001
$\Delta\rho_{\max}$	0.289	0.421
$\Delta\rho_{\min}$	-0.299	-0.335

Example 2: Synthesis of 4-(cycloheptyloxy)-3-(hydroxymethyl)-5-ethyl-6-methylpyridin-2(1H)-one (compound Z32)

[0041] Compound Z32 which corresponds to formula III



(formula III)

was synthesized, following a three-step protocol, as described below and as illustrated in Figure 3.

Step 1

[0042] In a first step, Diisopropyl azodicarboxylate (DIAD) (0.804g, 4 mmol) was added drop wise at room temperature to a solution of above-described intermediate A (0.63 g, 2 mmol), triphenylphosphine ($P\Phi_3$) (1.052g, 4 mmol) and cycloheptanol (0.456g, 4 mmol) in THF (20ml). After stirring overnight, the THF was evaporated and the residue

was suspended in a mixture of hexane and diethyl ether (50:50 v/v%). The precipitate was filtered off and the organic layer was evaporated. The residue obtained was purified using a silica gel column (e.g. a 60Å/0.040-
5 0.063mm ROCC column; eluent: pentane/dichloromethane, 50/50 v/v%), to give intermediate C (0.575 g, 70% yield).

Step 2

[0043] In a second step, Red-Al (2.3 ml, 7.6 mmol) was
10 suspended in benzene (10 ml). Intermediate C (1.77g, 4.3 mmol) was added to this solution, at 0°C. The mixture was heated at 75°C for 2 hours and then cooled again at 0°C. After addition of a solution of 20% sulphuric acid, the aqueous layer was extracted with dichloromethane. The
15 organic extracts were collected and washed with brine.

[0044] The crude product was chromatographed on silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: dichloromethane/pentane, 50/50 v/v%) to afford intermediate D (1.507 g, 95% yield).

20

Step 3

[0045] In a third step, Intermediate D (1.5g, 4 mmol) was then dissolved in a mixture of acetonitrile (10 ml) and dimethyl sulfide (2 ml). Trifluoroacetic acid (1ml) was
25 then added to this mixture, at 0°C. After stirring at room temperature for 3 hours, the solvents were evaporated. The residue was dissolved in dichloromethane and washed with a solution of saturated NaHCO₃.


[0046] After drying with MgSO₄ and evaporation of the
30 solvent, recrystallisation from ethyl acetate/hexane gave pure product Z32 as white crystals (mp = 146°C)

[0047] A nuclear magnetic resonance (NMR) ¹H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound Z32:

NMR ^1H for Z32: δ 13 (s, 1H), 4.6 (s, 2H), 4.1 (m, 1H), 2.44 (q, 2H), 2.31 (s, 3H), 1.7 (m, 12H), 1.1 (t, 3H)

Example 3: Synthesis of [4-(cycloheptyloxy)-5-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]methyl chloroacetate (compound Z33)

[0048] Compound Z33 which corresponds to formula IV



(formula IV)

was synthesized from compound Z32 as described below and as illustrated in Figure 4. Compound Z32 (165 mg, 0.6 mmol) was dissolved in dichloromethane (2ml) and pyridine (50 μ l). Chloroacetyl chloride (50 μ l) was added to this mixture cooled at 0°C. After stirring for 3 hours at 0°C, HCl (1ml, 1N) and dichloromethane (10ml) were added to this solution.

[0049] The organic layer was washed with a saturated NaCl solution and the crude product purified using a silica gel column (eluent: MeOH/CH₂Cl₂, 1/9) to give the crystalline product Z33 (0.160 g, Yield: 75%, mp = 123°C).


~~[0050] A nuclear magnetic resonance (NMR) ^1H profile~~

was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound Z33:

NMR ^1H for Z33: δ 13 (s, 1H), 5.2 (s, 2H), 4.2 (m, 1H), 4.0 (s, 2H), 2.5 (m, 2H), 2.3 (s, 3H), 1.7 (m, 12H), 1.1 (m, 3H)

Example 4: Synthesis of 2-(dimethylamino)ethyl 4-[(3,5-dimethylcyclohexyl)oxyl]-5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (compound Z53)

[0051] Compound Z53 which corresponds to formula V



(formula V)

5

was synthesized from compound Z37 as described below and as illustrated in Figure 5. To a solution of Z37 (0.167g, 0.5 mmol) in N,N-diethylethanolamine (3ml) was added a catalytic amount of tetraisopropyl titanate (c.a. 30 mg).


10 The mixture was stirred overnight at 110°C.

[0052] The solvent was then evaporated under vacuum and the residue was extracted with dichloromethane. The crude product was purified with a silica gel column (eluent: dichloromethane/ethanol, 90/10) to give product
15 Z53 (0.121 g, 60% yield, oil).

[0053] A nuclear magnetic resonance (NMR) ¹H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound Z53:
NMR ¹H for Z53: δ 12.8 (s, 1H), 4.7 (m, 1H), 4.3 (t, 2H),
20 2.9-2.4 (m, 6H), 2.3 (s, 3H), 2.1-1.4 (m, 8H), 1.25-0.7 (m, 17H).

Example 5: Synthesis of ethyl 5-ethyl-6-methyl-4-[(3-methylbut-2-enoyl)oxyl]-2-oxo-1,2-dihydropyridine-3-carboxylate (compound M18)
25

[0054] Compound M18 which corresponds to formula VI



(formula VI)

was synthesized as described below and as illustrated in Figure 6. Intermediate B0 (0.338g, 1.5 mmol) was dissolved in dichloromethane (10 ml) and pyridine (1 ml). 3,3-dimethyl acryloyl chloride (0.360g, 3.0 mmol) was added to this solution at 0°C and the solution was stirred overnight. The solvents were then removed in vacuo. Purification by silica gel chromatography (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: ethanol/dichloromethane, 98/02 v/v%) gave product M18 (0.270g, 60% yield, mp = 166°C).

[0055] A nuclear magnetic resonance (NMR) 1H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound M18:

15 NMR 1H for M18: δ 13 (s, 1H), 5.9 (s, 1H), 4.2 (q, 2H), 2.5 (m, 2H), 2.3 (s, 3H), 2.2 (s, 3H), 2.0 (s, 3H), 1.3 (t, 3H), 1.1 (t, 3H).

[0056] Compounds Z12, Z25, Z30, Z54 and Z55 were synthesized in a similar way as compound Z37. The protocol is similar except for the alcohol used in the second step, which is 2-chlorocyclohexanol for Z12, cycloheptanol for Z25, 3-methylcyclohexanol for Z30, cyclooctanol for Z54 and 4-ethylcyclohexanol for Z55.

25

[0057] Table 2 provides information on the structure and physico-chemical properties of specific compounds according to the invention, such as the nature of the side

groups R1 and R2 and of the spacer X, the melting point of the compound and its molecular weight.

Table 2: Structure and physico-chemical properties of 5 specific compounds (N°) according to the invention
















N°	X	R1	R2	mp (°C)	Molecular Weight
M18	O	CO ₂ Et		166	Calculated: 307 Measured: 307
Z12	O	CO ₂ Et		oil	Calculated: 341 Measured: 341
Z25	O	CO ₂ Et		112	Calculated: 321 Measured: 321
Z30	O	CO ₂ Et		oil	Calculated: 321 Measured: 321
Z32	O	CH ₂ OH		146	Calculated: 279 Measured: 279
Z33	O			123	Calculated: 355 Measured: 355
Z37	O	CO ₂ Et		108	Calculated: 335 Measured: 335
Z53	O			oil	Calculated: 406 Measured: 406
Z54	O	CO ₂ Et		104	Calculated: 335 Measured: 335

Table 2: Continuation

Z55		CO ₂ Et		100	Calculated: 335 Measured: 335
Z57		CO ₂ Et		oil	Calculated: 335 Measured: 335

Oil = viscous liquid formation

[0058] Examples 6 to 7 demonstrate that the compounds of the present invention are very efficient NNRTIs with HIV-1 inhibiting activity. This is illustrated via *in vitro* reverse transcriptase assays and via anti-HIV assays using P4 cell lines. The P4 cell line contains a LacZ gene under the transcriptional control of HIV-1 LTR elements.

10 [0059] For the *in vitro* inhibition studies of the HIV-1 reverse transcriptase activity, stock solutions of the compounds of the present invention were prepared in dimethyl sulfoxide at a final concentration of 10mM and kept at room temperature. Nevirapine was purchased from 15 Boehringer Ingelheim.

[0060] For the antiviral and the cytotoxicity assays, the drugs were diluted in complete DMEM medium. In these experiments, drugs were diluted in triplicate wells in a 96-well plate in six, 5 fold serial dilutions.

Example 6: Effect of the compounds according to the invention on the reverse transcriptase activity in vitro of HIV-1

HIV-1 reverse transcriptase activity:

5 [0061] In vitro inhibition studies used a fixed-time assay for HIV-1 reverse transcriptase RNA dependent DNA polymerase activity. RT was purchased from VWR (ref CAL382129-500). One unit of RT corresponds to the amount of enzyme which incorporates one nanomole of [³H]TTP in 10
10 minutes at 37°C.

[0062] Assays were performed in a final volume of 50µl. The mixture contained 0.125 units of RT, 10 mM MgCl₂, 2mM DTT, 50mM Tris pH 8.3, 50mM KCl, 1µg/µl BSA, 0.01% triton X100, 20 µg/ml (0.4 A260/ml) poly(rC)-oligo(dG)₁₂₋₁₈,
15 1µCi [³H]dGTP and 1µl of the inhibitor (dissolved in dimethyl sulfoxide, DMSO). Reaction mixtures were incubated at 37°C for 10 min. The incorporation rate was determined by a standard trichloroacetic acid precipitation procedure (adapted from Current protocols in molecular biology. Eds
20 Wiley, MGH Harvard medical school) and liquid scintillation counting using a Wallac scintillation counter.

Production of Viral stocks:

[0063] Wurzburg Jurkat T cells (subclone JR) were
25 transfected with 10 µg of the circularly permuted infectious molecular clone HIV_{PNL4-3} (Adachi et al., 1986. J. Virol, 59 (2), p284-291). Two days later, co-cultivation with SupT1 cells (a human T-cell lymphoma cell line) was initiated to facilitate rapid production of progeny
30 virions. Production of virus was measured by using the Innostest HIV Antigen mAb p24 kit (Innogenetics). At the peak of production cultures were harvested and filtered. The amount of virus produced was measured by p24 ELISA

experiments and the virus stocks were stored at -80°C until used.

[0064] Results for some of the compounds according to the invention are summarized in Table 3. The *in vitro* activity of the compounds, at a final concentration of 10 μM , on the reverse transcriptase (RT) activity of HIV-1 is derivable from the relative (%) reduction in RT activity. Hereby, the RT activity in the absence of any of the compounds is set at 100%. From table 3 it is evident that all of the compounds tested were able to reduce the *in vitro* RT activity by at least about 30 %. Most of the compounds tested reduced the activity by at least 50% to 60%. The most active compound, Z37inv, reduced the activity to about 6% only of the control. This activity is slightly better than the one of Nevirapine, a common NNRTI.

Table 3: *In vitro* residual RT activity after addition of some compounds (N°) belonging to the invention. Comparison with Nevirapine, a common RT inhibitor

N°	Relative (%) RT activity <i>in vitro</i> (compound added at 10 μM)
M18	70.8
Z12	63.7
Z25	34.6
Z30	22.0
Z32	44.0
Z33	42.0
Z37	8.3
Z37A	11.7
Z37B	8.0
Z37inv	6.7
Z53	26.5
Z54	19.4

Z55	28.8
Z57	ND
Nevirapine	8.6

ND, not determined

Example 7: Anti-HIV activity (EC_{50} value expressed in μM) on P4 cells and cytotoxicity (CC_{50} value expressed in μM) of some of the compounds according to the invention

P4 Cell line:

[0065] Anti-HIV activity and cytotoxicity of the compounds were tested on a P4 cell line. The P4 cell line (Clavel & Charneau, 1994. J. Virol., Vol.68 p1179-1185) was provided by Dr. François Clavel (Unité de recherche antivirale de l'hôpital Xavier Bichat Paris: Inserm). These p4 cells were cultured in complete DMEM medium supplemented with 10% fetal bovine serum (FBS), 0.5 % of Penicillin/Streptomycin and G418 at 0.5 mg/ml. Exponentially growing cells were trypsinized, centrifuged and split twice weekly at $5 \cdot 10^4$ cells/ml.

Cytotoxicity of the compounds

[0066] The 50 % cytotoxic concentration (CC_{50}) was determined using a protocol adapted from Pauwels et al. (1988. J. Virol. Methods 20(4):309-21). Briefly, flat bottom 96-well plates were filled with 50 μl of complete medium containing $5 \cdot 10^3$ P4 cells. 2 hours later 50 μl of drug solution were added to the cells. Drugs (dissolved in DMEM, see above) were diluted in six, 5-fold serial dilutions from stock solutions in triplicate wells of a 96-well plate. Cells and compounds were incubated at 37°C in growth medium for 3 days. Cell viability was determined by MTT assays using the Roche Cell Proliferation KIT. The absorbance ($\lambda=570nm$) was measured on a Benchmark™

Microplate Reader (Biorad) and compared with 12 cell control replicates (no drug added). Each assay was performed at least three times for a total of at least nine replicate wells. This method detects both cytostatic and
 5 cytolytic effects of drugs.

Anti-HIV assay

[0067] The P4 cell line is a cell line of HIV-infectible Hela-CD4 cells that carry the bacterial lacZ
 10 gene under the control of the HIV-1 long terminal repeat (LTR). In this cell line, transcription of the LacZ gene is driven by the HIV-1 LTR. As such, the cytoplasmic accumulation of β -galactosidase is strictly dependent on the presence of the HIV transactivator Tat produced during
 15 the intracellular viral replication (Clavel & Charneau, 1994. J. Virol., Vol.68, p. 1179-1185). In other words, in this system, the expression level of the β -galactosidase gene is proportional to the viral replication.

[0068] In a particular embodiment, the p4 cell line
 20 was infected with a HIV strain having a mutant RT characterized by a Cystein for Tyrosine substitution (Y188C mutation). This mutant HIV cell line was produced as follows. In a first step, the Y188C mutation was introduced by site directed mutagenesis on the circularly permuted
 25 ~~infectious molecular clone HIV_{PMT4-3}. In a second step, the~~
 resulting plasmid was transfected in Jurkat cells and the mutant viruses produced were purified as indicated above.

[0069] Briefly, in the anti-HiV assays used here 100
 30 μ l of P4 cells were plated in 96-well plate at a concentration of 0.4×10^5 cells/ml and incubated at 37°C, 5 % CO₂. After 48h, the medium was removed and 100 μ l of the different drugs dilutions were added to the cells. Four hours after the addition of the drugs all cells were

infected with equal amount of cell-free virus, corresponding to 100 ng of HIV p24 antigen. After 48h of incubation at 37°C, 5% CO₂, β -galactosidase activity was measured using chlorophenol red- β -D-galactopyranoside
5 assays.

[0070] The absorbance was measured on a Benchmark™ Microplate Reader (Biorad) (λ =570nm) and compared with 12 cell control replicates (no virus or drug added) and 12 virus control wells (no drug added). Each assay was
10 performed a minimum of three times. The 50 % effective concentration (EC₅₀) was calculated from each dose response curve using the CurveExpert 1.3 software. As Nevirapine activity corresponds to its published values (10-100 nM), the data are consistent with other measures of viral
15 replication.

[0071] The results of both tests are summarized in columns 2, 3 and 4 of Tables 4 and 5. From these tables it can be derived that the compounds according to the invention have good to excellent EC₅₀ values and are able
20 to inhibit HIV-1 activity. Compound Z37inv gave the best result and is more active than Nevirapine. It displays a good selectivity index (SI) due to this high antiviral activity combined with a low cytotoxicity.

[0072] That some of the compounds, for instance
25 compound Z37, are active on HIV-1 mutant strains resistant to Nevirapine is evident from Table 5.

[0073] From the above it is evident that the compounds according to the invention have very good anti-HIV activity. The demonstrated low cytotoxicity is a first
30 indication that the compounds could be very useful in the treatment of HIV and especially HIV-1 infected individuals.

Table 4: *Ex vivo* anti-HIV activity (EC_{50}), cytotoxicity (CC_{50}) and SI (selectivity index = CC_{50}/EC_{50}) for some compounds according to the invention, the test being performed on a P4 cell line with a WT (wild-type) RT.

5 Comparison with Nevirapine, a common RT inhibitor

N°	EC_{50} WT (μM)	CC_{50} (μM)	SI
M18	5.82	>100	>17
Z12	2.53	>100	>40
Z25	0.48	81	168
Z30	0.52	>100	>192
Z32	1.16	55	47
Z33	1.03	54	52
Z37	0.043	58	1349
Z37A	0.240	63	263
Z37B	0.091	72	791
Z37inv	0.021	64	>3047
Z53	>>4	33	<8
Z54	1.34	58	43
Z55	>>4	57	<14
Z57	1.82	ND	ND
Nevirapine	0.030	>100	>3333

ND, not yet determined

BEST AVAILABLE COPY

Table 5: *Ex vivo* anti-HIV activity (EC_{50}), cytotoxicity (CC_{50}) and SI (selectivity index = CC_{50}/EC_{50}) for some compounds according to the invention, the test being performed on a P4 cell line with a mutant RT characterized by a Cystein for Tyrosine substitution at codon 188 (Cys188) in the RT. Comparison with Nevirapine, a common RT inhibitor

N°	EC_{50} Cys188RT (μ M)	CC_{50} (μ M)	SI
M18	5.38	>100	>18
Z37	0.006	58	9667
Z37A	0.039	63	1615
Z37B	0.025	72	2880
Z37inv	0.010	64	6400
Z53	>4	33	<8
Z54	0.120	58	483
Z55	0.406	57	140
Nevirapine	2.77	>100	36.1

[0074] From the above, it is evident that in contrast to Nevirapine, some compounds of the invention are active against Cys188 mutant strains.

[0075] The compounds according to the present invention could be administrated orally to humans in a dosage range of 1 to 100 mg/kg body weight in divided doses. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may vary and will depend upon a variety of factors including the activity of the compound employed, its metabolic stability and length of action, as well as the age, the weight and the general health of the patient at the time of the administration, the rate of excretion, the other drugs used, and the host undergoing therapy. It falls

within the skills of an artisan to determine the concentration of drugs that should be used in HIV-1 treatment.

[0076] The compounds of the present invention can be used for the preparation of medicaments such as therapeutic compositions for the treatment of HIV-1 related diseases. The compounds can be used alone (in pure form, as salt or as prodrug), or as mixtures of several compounds, whether or not in combination with other compounds active against HIV-1 infections.

[0077] Such anti-viral agents include other NNRTIs such as Nevirapine, Efavirenz, Delavirdine, Capravirine and the like as well as NRTIs, protease inhibitors, fusion/binding inhibitors, integrase inhibitors, pyrophosphate analogue RT inhibitors and/or HIV vaccines. The above list is not exhaustive and may include any other anti-viral, anti-infective, antibiotic as well as any immunomodulator. The effect can be additive and/or synergistic.

[0078] The compounds according to the invention and mixtures thereof with any other therapeutic and/or pharmaceutical agent can be used in pharmaceutical compositions comprising an acceptable diluent and/or carrier. These are known to a skilled person.


[0079] Administration in the case of combinations can be together or consecutively whereby the interval can range from minutes to hours. It is evident that other applications than oral applications are possible, for instance in the case of combination with a therapeutic and/or prophylactic vaccine. It is further evident that the compounds according to the inventions can be applied under any form that does not preclude their activity, such forms including pills, liquids, powders, pastes and any other form or formulation known in the art.

BEST AVAILABLE COPY

Example 8: Comparison of some compounds according to the invention with compounds disclosed in prior art and influence of the R2 type on the activity of the compound

[0080] Compounds according to the present invention were compared with compounds known in the art. Provided that any group that is linked to position 4 of the pyridinone ring is hereby referenced as "R2", and X is defined as the "spacer" between the two groups, the following can be concluded

10



[0081] Compounds disclosed in patents EP 0 462 800 and EP 0 481 802 differ by their substitution in position 3 and differ by their substitution in position 4 (no spacer between the pyridinone and R2 in the compounds disclosed in EP 0462 800 and EP 0 481 802 whereas all compounds of the present invention have such a spacer).

[0082] The compounds disclosed in patent EP 0 462 808 differ by their substitution in position 3 (all possess a phthaloyl group on this position). They are further not substituted in position 4.

[0083] The compounds disclosed in WO97/05113 differ by their substitution in position 4. Only arylthio groups are considered, whereas compounds of the invention do not feature any arylthio group in position 4.






[0084] The compounds disclosed in WO99/55676 differ by their substitution in position 3. Only amino or alkylamino groups have been considered. None of these chemical functions is present in the invention.

[0085] Compounds disclosed in International patent application WO02/24650 are of the above the compounds most closely related with those of the present invention, the compounds having a spacer between the pyridinone ring and
5 R2, the R2 groups at first sight maybe comparable. However, the specific compounds disclosed in WO02/24650 to have anti-HIV activity all feature an aryl substituent at position 4 of the pyridinone ring, unlike compounds of the present invention. No compound bearing a C₇₊ cycloalkyl or
10 a substituted cycloalkyl in position 4 is disclosed and/or claimed in International patent application WO02/24650.

[0086] The following table 6 demonstrates the interest of for instance C₇₊ cycloalkyls or substituted cycloalkyls as evident from the EC50 value:

15

Table 6: Effect of the R2 substituent on EC₅₀ values

		
R2	EC ₅₀ WT (μM)	EC ₅₀ Cys188RT (μM)
	1.91	ND
	0.77	6.5
 (formula VII, Z25)	0.48	3.28
 (formula II, Z37)	0.043	0.006

ND, not determined

[0087] As shown in Table 6, replacement of a
 5 cyclopentyl or cyclohexyl by a cycloheptyl leads to an increase in antiviral potency of the compounds.

[0088] Replacement of a cyclohexyl by a m,m-dimethyl-cyclohexyl leads to a 16-fold increase in antiviral potency.

10 [0089] Furthermore, compounds Z25 and Z37 are more active on Cys188 mutant strains than the cyclohexyl derivative.

[0090] It goes beyond any doubt that the above examples are sufficient to demonstrate that the problem of


providing alternative compounds active against HIV-1, with pronounced NNRTI activity, is solved by the compounds according to the invention which are novel and inventive.

[0091] Advantageously, compounds according to the
5 invention can be active against HIV-1 strains that are resistant to NNRTIs currently used such as Nevirapine.

BEST AVAILABLE COPY

CLAIMS


1. A 5-ethyl-6-methyl-2-pyridinone derivative compound according to general formula I,



(formula I)

5 wherein


X = O, S, NH, $\text{C}=\text{O}$, $(\text{C}_n\text{H}_{2n})$, $(\text{C}_n\text{H}_{2n})\text{O}$, $\text{O}(\text{C}_n\text{H}_{2n})$, $(\text{C}_n\text{H}_{2n})\text{S}$, $\text{S}(\text{C}_n\text{H}_{2n})$ with $n = 1-4$



with $n, m = 0 - 8$

Ar = Aromatic ring selected from : phenyl, pyridyl, thiazolyl, furanyl, thiophenyl, benzofuranyl, benzothiophenyl, benzothiazolyl, imidazolyl, indolyl, each optionally substituted with up to 4 substituents selected from : halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} alkylamino, amino, C_{1-4} aminoalkyl, C_{1-4} alkylcarbonyl, C_{1-4} dialkylamino, azido

Y = H, halo, alkylamino, dialkylamino, nitrile, hydroxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy, C₅₋₇ cycloalkyl optionally substituted with up to 4 substituents selected from : halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, nitrile; or Y can be :



R₂ = C₇₋₉ cycloalkyl;

C₅₋₈ cycloalkyl substituted with up to 4 substituents;

C₅₋₈cycloalkenyl optionally substituted with up to 4 substituents;


C₅₋₈aliphatic heterocycle optionally substituted with up to 4 substituents;

C₆₋₉bridged cycloalkyl optionally substituted with up to 4 substituents;


C₆₋₉bridged cycloalkenyl optionally substituted with up to 4 substituents;

substituents selected from :

halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, CN;



Or R2 can be :




2. The compound according to claim 1 further characterized in that it has a substituted cycloalkyl group as R2 in position 4 of the pyridinone ring.


3. The compound according to claim 2 further characterized in that said substituted cycloalkyl group is a 3,5-dimethylcyclohexyl moiety.

4. The compound according to claim 1 further characterized in that it has a C7-9 cycloalkyl group as R2 in position 4 of the pyridinone ring.


5. The compound according to claim 1 selected from the group consisting of compounds which correspond to




: formula II




: formula III




: formula IV



: formula V



: formula VI



: formula VII

BEST AVAILABLE COPY

6. A pharmaceutical composition comprising at least one the compounds according to any of claims 1 to 5 and an acceptable carrier and/or diluent.

7. The composition according to claim 6
5 further comprising another anti-viral agent.

8. The composition according to claim 7, characterized in that said anti-viral agent is Nevirapine.

9. Use of the compound or the composition according to any of the preceding claims 1 to 8 for the
10 preparation of a medicament in the treatment and/or the prevention of HIV-1 infections.

10. The use according to the claim 9 for the preparation of a medicament for the treatment and/or prevention of HIV-1 infections by a strain resistant to at
15 least one anti-viral agent.

11. The use of claim 10 wherein said anti-viral agent is Nevirapine.


12. A production process for a compound according to claim 5.

ABSTRACT2-PYRIDINONE DERIVATIVES, HAVING HIV INHIBITING PROPERTIES

5


The present invention relates to 2-Pyridinone derivatives, more specifically 5-ethyl-6-methyl-2-pyridinone derivatives, according to general formula I that inhibit human immunodeficiency virus type 1 (HIV-1) replication and are therefore of interest in the treatment of Acquired Immune Deficiency Syndrome (AIDS). The present invention further relates to the synthesis of said compounds and their use, with or without other pharmaceutical agents, in the treatment of AIDS and viral infections by HIV-1.

15



(Fig. 7)

20

Fig. 1




Fig. 2A








Fig. 2B

Fig. 3

Fig. 4Fig. 5Fig. 6





Fig. 7

BEST AVAILABLE COPY

PCT/BE2004/000134



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.